ArticleDiscover oncology2026
LncRNA NRAV is associated with unfavorable prognosis and immune-related transcriptional features in hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) remains a lethal malignancy, and robust biomarkers are needed to refine risk stratification and support clinical decision-making. Long noncoding RNAs can shape tumor biology and immune states. We investigated the clinical relevance of lncRNA NRAV in HCC and its association with immune-related features.
methodsNRAV expression and clinical associations were assessed using TCGA-LIHC, paired tumor-adjacent tissue comparisons, GTEx normal liver controls, and independent GEO cohorts. Prognostic associations were evaluated by Kaplan-Meier and Cox regression analyses. Immune features were profiled using ssGSEA and correlation analyses with immune checkpoint molecules. Functional effects of NRAV were examined in HCC cells using loss-of-function assays.
resultsNRAV was consistently overexpressed in HCC compared with normal liver tissues across multiple cohorts and paired tumor-normal samples. Higher NRAV expression was associated with adverse clinicopathological features and poorer overall survival. ROC analysis showed that NRAV expression had good discriminatory performance in HCC (AUC = 0.901, 95% CI: 0.865-0.937). Immune analyses showed that NRAV-high tumors were associated with reduced CD8⁺ T-cell-related signatures and increased macrophage- and Th2-associated signatures, together with elevated expression of multiple immune checkpoint molecules (e.g., PDCD1, CD274, CTLA4, LAG3, and HAVCR2). In vitro, NRAV knockdown suppressed colony formation, migration, and invasion in HCC cells.
conclusionNRAV is upregulated in HCC and is associated with unfavorable prognosis, adverse clinicopathological features, and immune-related transcriptional patterns. NRAV may represent a candidate biomarker for risk assessment and warrants further mechanistic and translational investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.